OncoC4

Focus: OncoC4 is a Rockville-based immunotherapy biotech specializing in antibodies and cancer immunotherapies targeting oncology indications. The company operates at an early-stage development scale with a focused pipeline in immuno-oncology.

Oncology Cancer Immunotherapy Unknown

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About OncoC4

AI assessmentNot Hiring

No open roles listed right now. Follow OncoC4 to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ONC-841

Advanced Solid Tumor

PHASE_1

Clinical Trials (1)

NCT06219499Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

Phase 1

Help build intelligence for OncoC4

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with multiple Phase 1/2 programs across high-value oncology indications (lung cancer, prostate cancer, melanoma, ovarian cancer)
Specialized focus on antibodies and immunotherapies positions you in a high-growth modality with strong biotech talent demand
Clinical Research and Clinical Operations hiring indicates active trial expansion and near-term data generation catalysts

Watch Out For

Pre-revenue biotech with no disclosed funding, cash position, or financial backing—sustainability and runway unclear
Only 4 active job openings and limited scale (no employee count disclosed) suggest constrained growth opportunities and potential compensation limits

Generated by Claude from OncoC4's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ONC-783

Advanced Solid Tumor

PHASE_1

Clinical Trials (1)

NCT07408258Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

Phase 1

ONC-841

Advanced Solid Tumor

PHASE_1

Clinical Trials (1)

NCT06352359Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Phase 1